All In Biotech

Free tool

FAERS Monitor: Nyvepria

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761111 or its brand name (Nyvepria, Pegfilgrastim-Apgf). Reports on generic versions are filed under their own applications.

Reports

198

Serious

118

60% of reports

Hospitalization

68

Death reported

22

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death23
  • off label use17
  • pyrexia15
  • drug dose omission by device12
  • device leakage11
  • nausea11
  • fatigue10
  • asthenia9
  • diarrhoea7
  • neutropenia7
  • device issue6
  • device operational issue6
  • hospitalisation6
  • decreased appetite5
  • dyspepsia5

Reports by year received

View as table
YearReports
20213
202217
202335
202453
202567
202623

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,961 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
device operational issueSignal6148.467.4736
device leakageSignal1127.015.2250
drug dose omission by deviceSignal1216.39.4158
device issueSignal67.13.226
neutropeniaSignal75.52.621
dyspepsiaSignal55.42.314
pyrexiaSignal154.62.839
hospitalisationSignal64.11.911
deathSignal232.81.927
astheniaSignal92.51.37
decreased appetite52.31.02
off label useSignal172.11.39
nausea111.50.81
fatigue101.40.71
diarrhoea71.20.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.